Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 8
1993 13
1994 10
1995 59
1996 37
1997 37
1998 49
1999 45
2000 48
2001 49
2002 44
2003 44
2004 37
2005 44
2006 36
2007 31
2008 31
2009 34
2010 39
2011 33
2012 30
2013 39
2014 26
2015 26
2016 23
2017 16
2018 21
2019 21
2020 10
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

895 results
Results by year
Filters applied: . Clear all
Page 1
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K. Ashida K, et al. Aliment Pharmacol Ther. 2016 Jan;43(2):240-51. doi: 10.1111/apt.13461. Epub 2015 Nov 11. Aliment Pharmacol Ther. 2016. PMID: 26559637 Free PMC article. Clinical Trial.

The proportion of patients with healed EE up to week 8 was 99.0% for vonoprazan (203/205) and 95.5% for lansoprazole (190/199), thus verifying the non-inferiority of vonoprazan (P < 0.0001). ...Overall, vonoprazan was well-tolerated. CONCLUSIONS: The non-inferiority of

The proportion of patients with healed EE up to week 8 was 99.0% for vonoprazan (203/205) and 95.5% for lansoprazole (190/199), thus …
Family History of Gastric Cancer and Helicobacter pylori Treatment.
Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, Joo J. Choi IJ, et al. N Engl J Med. 2020 Jan 30;382(5):427-436. doi: 10.1056/NEJMoa1909666. N Engl J Med. 2020. PMID: 31995688 Clinical Trial.
We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days) or placebo. ...
We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy (lansoprazole [30 mg], amoxicil …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazo
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, Moon JS, Lim YJ, Kang DH, Cheon GJ, Baik GH, Kim KO, Cho KB, Jang JS, Park JJ, Son BK, Jung HK, Kim BW, Kim SK, Lee ST, Cha JM, Kim AR, Kim EJ, Park HW, Song GS. Cho YK, et al. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865. Epub 2020 Jul 23. Aliment Pharmacol Ther. 2020. PMID: 32701188 Free PMC article. Clinical Trial.
In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 we …
In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg a …
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P Jr, Katz PO, Chen Y, Sostek M. Miner P Jr, et al. Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. METHODS: This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragast …
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omepr …
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K. Kawai T, et al. Gut. 2018 Jun;67(6):1033-1041. doi: 10.1136/gutjnl-2017-314852. Epub 2017 Dec 1. Gut. 2018. PMID: 29196436 Free PMC article. Clinical Trial.
Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc analyses of the extension study, peptic ulcer recurrence rates were significantly lower with vonoprazan 10 mg (log-rank test, P=0.039), but not …
Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc anal …
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, Watari J, Miwa H. Oshima T, et al. Aliment Pharmacol Ther. 2019 Jan;49(2):140-146. doi: 10.1111/apt.15062. Aliment Pharmacol Ther. 2019. PMID: 30589965 Clinical Trial.

RESULTS: Heartburn was relieved sooner with vonoprazan than with lansoprazole (P < 0.05, log-rank test). Heartburn was completely relieved in 31.3% and 12.5% of patients on day 1 with vonoprazan and lansoprazole, respectively. Significantly more patients achieved

RESULTS: Heartburn was relieved sooner with vonoprazan than with lansoprazole (P < 0.05, log-rank test). Heartburn was completely

Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Wong GLH, Lau LHS, Ching JYL, Tse YK, Ling RHY, Wong VWS, Chiu PWY, Lau JYW, Chan FKL. Wong GLH, et al. Gut. 2020 Apr;69(4):652-657. doi: 10.1136/gutjnl-2019-318715. Epub 2019 Jun 22. Gut. 2020. PMID: 31229990 Clinical Trial.
Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer). The cumulative incidence of recurrent upper GI bleeding in 24 months was 0.88% (95% CI 0.08% to 4.37%) in …
Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastr …
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E. Ashida K, et al. World J Gastroenterol. 2018 Apr 14;24(14):1550-1561. doi: 10.3748/wjg.v24.i14.1550. World J Gastroenterol. 2018. PMID: 29662293 Free PMC article. Clinical Trial.
AIM: To compare vonoprazan 10 and 20 mg vs lansoprazole 15 mg as maintenance therapy in healed erosive esophagitis (EE). ...The safety profiles of vonoprazan 10 and 20 mg were similar to that of lansoprazole 15 mg in patients with healed EE. Treatment-related AEs we …
AIM: To compare vonoprazan 10 and 20 mg vs lansoprazole 15 mg as maintenance therapy in healed erosive esophagitis (EE). ...The safet …
Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial.
O'Hara J, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Wood R, Wilson JA. O'Hara J, et al. BMJ. 2021 Jan 7;372:m4903. doi: 10.1136/bmj.m4903. BMJ. 2021. PMID: 33414239 Free PMC article. Clinical Trial.
Mean RSI scores were similar between treatment arms at baseline: lansoprazole 22.0 (95% confidence interval 20.4 to 23.6) and placebo 21.7 (20.5 to 23.0). ...Lansoprazole showed no benefits over placebo for any secondary outcome measure, including RSI scores at 12 m …
Mean RSI scores were similar between treatment arms at baseline: lansoprazole 22.0 (95% confidence interval 20.4 to 23.6) and placebo …
895 results